Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
263 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Brain Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Brain Cancer - Pipeline Review, H1 2015', provides an overview of the Brain Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Brain Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Brain Cancer - Overview 10 Pipeline Products for Brain Cancer - Comparative Analysis 11 Brain Cancer - Therapeutics under Development by Companies 12 Brain Cancer - Therapeutics under Investigation by Universities/Institutes 16 Brain Cancer - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Brain Cancer - Products under Development by Companies 20 Brain Cancer - Products under Investigation by Universities/Institutes 24 Brain Cancer - Companies Involved in Therapeutics Development 25 AbbVie Inc. 25 AngioChem Inc. 26 Arrien Pharmaceuticals, LLC 27 BBB Therapeutics B.V. 28 biOasis Technologies Inc. 29 Bionomics Limited 30 Bristol-Myers Squibb Company 31 Cavion LLC 32 Critical Outcome Technologies Inc. 33 CureFAKtor Pharmaceuticals, LLC 34 Diffusion Pharmaceuticals LLC 35 e-Therapeutics plc 36 Eisai Co., Ltd. 37 Exelixis, Inc. 38 GlaxoSmithKline plc 39 Hutchison MediPharma Limited 40 Merrimack Pharmaceuticals, Inc. 41 Nanobiotix 42 Nektar Therapeutics 43 Nerviano Medical Sciences S.r.l. 44 Neuralstem, Inc. 45 Novartis AG 46 Oncology Research International Limited 47 Pfizer Inc. 48 Philogen S.p.A. 49 Phosplatin Therapeutics 50 Prana Biotechnology Limited 51 Puma Biotechnology, Inc. 52 RadioRx, Inc. 53 Sagetis Biotech, S.L. 54 Sanofi 55 Spectrum Pharmaceuticals, Inc. 56 Stemline Therapeutics, Inc. 57 Takeda Pharmaceutical Company Limited 58 ThromboGenics NV 59 Tocagen Inc. 60 Zymeworks Inc. 61 Brain Cancer - Therapeutics Assessment 62 Assessment by Monotherapy Products 62 Assessment by Combination Products 63 Assessment by Target 64 Assessment by Mechanism of Action 67 Assessment by Route of Administration 70 Assessment by Molecule Type 72 Drug Profiles 74 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 74 2B3-101 - Drug Profile 76 ANG-1005 - Drug Profile 78 ANG-4043 - Drug Profile 80 ARN-7016 - Drug Profile 81 BNC-105 - Drug Profile 82 BT-2111 - Drug Profile 83 cabazitaxel - Drug Profile 84 cabozantinib s-malate - Drug Profile 86 CFAKC-4 - Drug Profile 89 COTI-2 - Drug Profile 90 dabrafenib mesylate - Drug Profile 93 dacomitinib - Drug Profile 96 dexanabinol - Drug Profile 98 Drug for Brain Metastasis - Drug Profile 100 erismodegib - Drug Profile 101 etirinotecan pegol - Drug Profile 104 Gene Therapy for Brain Cancer - Drug Profile 107 Gene Therapy to Activate p53 for Oncology - Drug Profile 108 HMPL-813 - Drug Profile 109 ipilimumab - Drug Profile 110 irinotecan sucrosofate liposomal - Drug Profile 113 KML-001 - Drug Profile 116 lapatinib ditosylate - Drug Profile 118 LEQ-506 - Drug Profile 122 lucanthone hydrochloride - Drug Profile 123 MDNA-55 - Drug Profile 125 mibefradil dihydrochloride - Drug Profile 126 Monoclonal Antibody for Brain Cancer and Metastatic Breast Cancer - Drug Profile 128 NBTX-IV - Drug Profile 129 neratinib - Drug Profile 130 nimotuzumab - Drug Profile 134 NMSE-973 - Drug Profile 137 NSI-566 - Drug Profile 138 ORIL-007 - Drug Profile 140 PB-357 - Drug Profile 141 PBT-519 - Drug Profile 142 pritumumab - Drug Profile 143 PT-112 - Drug Profile 145 RAD-1901 - Drug Profile 146 radretumab - Drug Profile 148 RRX-001 - Drug Profile 150 SAG-002 - Drug Profile 151 SAG-003 - Drug Profile 152 siomycin A - Drug Profile 153 SL-301 - Drug Profile 154 SL-302 - Drug Profile 155 Small Molecule for Brain Cancer - Drug Profile 156 Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile 157 Small Molecule for Oncology - Drug Profile 158 Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile 159 TB-403 - Drug Profile 160 TBX-02 - Drug Profile 162 TPI-287 - Drug Profile 163 transcrocetinate sodium - Drug Profile 165 TTL-1177 - Drug Profile 166 ubidecarenone - Drug Profile 167 Vaccine for Glioblastoma Multiforme - Drug Profile 169 veliparib - Drug Profile 170 vocimagene amiretrorepvec + flucytosine ER - Drug Profile 173 Brain Cancer - Recent Pipeline Updates 175 Brain Cancer - Dormant Projects 244 Brain Cancer - Discontinued Products 248 Brain Cancer - Product Development Milestones 249 Featured News & Press Releases 249 Appendix 258 Methodology 258 Coverage 258 Secondary Research 258 Primary Research 258 Expert Panel Validation 258 Contact Us 259 Disclaimer 259
List of Tables Number of Products under Development for Brain Cancer, H1 2015 14 Number of Products under Development for Brain Cancer - Comparative Analysis, H1 2015 15 Number of Products under Development by Companies, H1 2015 17 Number of Products under Development by Companies, H1 2015 (Contd..1) 18 Number of Products under Development by Companies, H1 2015 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2015 20 Comparative Analysis by Late Stage Development, H1 2015 21 Comparative Analysis by Clinical Stage Development, H1 2015 22 Comparative Analysis by Early Stage Development, H1 2015 23 Products under Development by Companies, H1 2015 24 Products under Development by Companies, H1 2015 (Contd..1) 25 Products under Development by Companies, H1 2015 (Contd..2) 26 Products under Development by Companies, H1 2015 (Contd..3) 27 Products under Investigation by Universities/Institutes, H1 2015 28 Brain Cancer - Pipeline by AbbVie Inc., H1 2015 29 Brain Cancer - Pipeline by AngioChem Inc., H1 2015 30 Brain Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 31 Brain Cancer - Pipeline by BBB Therapeutics B.V., H1 2015 32 Brain Cancer - Pipeline by biOasis Technologies Inc., H1 2015 33 Brain Cancer - Pipeline by Bionomics Limited, H1 2015 34 Brain Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 35 Brain Cancer - Pipeline by Cavion LLC, H1 2015 36 Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015 37 Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 38 Brain Cancer - Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 39 Brain Cancer - Pipeline by e-Therapeutics plc, H1 2015 40 Brain Cancer - Pipeline by Eisai Co., Ltd., H1 2015 41 Brain Cancer - Pipeline by Exelixis, Inc., H1 2015 42 Brain Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 43 Brain Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 44 Brain Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 45 Brain Cancer - Pipeline by Nanobiotix, H1 2015 46 Brain Cancer - Pipeline by Nektar Therapeutics, H1 2015 47 Brain Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 48 Brain Cancer - Pipeline by Neuralstem, Inc., H1 2015 49 Brain Cancer - Pipeline by Novartis AG, H1 2015 50 Brain Cancer - Pipeline by Oncology Research International Limited, H1 2015 51 Brain Cancer - Pipeline by Pfizer Inc., H1 2015 52 Brain Cancer - Pipeline by Philogen S.p.A., H1 2015 53 Brain Cancer - Pipeline by Phosplatin Therapeutics, H1 2015 54 Brain Cancer - Pipeline by Prana Biotechnology Limited, H1 2015 55 Brain Cancer - Pipeline by Puma Biotechnology, Inc., H1 2015 56 Brain Cancer - Pipeline by RadioRx, Inc., H1 2015 57 Brain Cancer - Pipeline by Sagetis Biotech, S.L., H1 2015 58 Brain Cancer - Pipeline by Sanofi, H1 2015 59 Brain Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 60 Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2015 61 Brain Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 62 Brain Cancer - Pipeline by ThromboGenics NV, H1 2015 63 Brain Cancer - Pipeline by Tocagen Inc., H1 2015 64 Brain Cancer - Pipeline by Zymeworks Inc., H1 2015 65 Assessment by Monotherapy Products, H1 2015 66 Assessment by Combination Products, H1 2015 67 Number of Products by Stage and Target, H1 2015 69 Number of Products by Stage and Mechanism of Action, H1 2015 72 Number of Products by Stage and Route of Administration, H1 2015 75 Number of Products by Stage and Molecule Type, H1 2015 77 Brain Cancer Therapeutics - Recent Pipeline Updates, H1 2015 179 Brain Cancer - Dormant Projects, H1 2015 248 Brain Cancer - Dormant Projects (Contd..1), H1 2015 249 Brain Cancer - Dormant Projects (Contd..2), H1 2015 250 Brain Cancer - Dormant Projects (Contd..3), H1 2015 251 Brain Cancer - Discontinued Products, H1 2015 252
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
